Haleon plc (HLN) Stock
HLN has an Alpha Score of 35 out of 100 (weak), computed on Nov 3, 2026 from 3 of 4 sub-scores. 4 members of Congress disclosed 14 trades in HLN since 2023: 9 purchases and 5 sales, most recently Valerie Hoyle (sale, Sep 23, 2025). 6 of the hedge funds AlphaScala tracks reported HLN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $86.44M. Its trailing P/E ratio is 17.2 and its net margin 14.5% (key statistics as of Oct 31, 2026).
What is HLN's Alpha Score?
How it works →Alpha Score of 35 reflects weak overall profile with poor momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 3, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Haleon plc (HLN)?
Most recent: Valerie Hoyle (sale, Sep 23, 2025); records start Jan 13, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Val Hoyle D-OR · House | 2025-09-23 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-07-10 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-24 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2025-04-09 | partial sale | $1k – $15k |
| Val Hoyle D-OR · House | 2024-10-29 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-06-21 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-05-20 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-07-21 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all HLN political trades →Which hedge funds own HLN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 9.26M | $86.44M | +41% |
| D.E. Shaw David Shaw | 2.53M | $23.56M | +1108% |
| Citadel Ken Griffin | 1.66M | $15.52M | +66% |
| Millennium Management Israel Englander | 932K | $8.70M | NEW |
| Bridgewater Associates Ray Dalio | 403K | $3.76M | NEW |
| Marshall Wace | 87K | $807.8K | -68% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are HLN's key statistics?
Key statistics as of Oct 31, 2026
How does HLN's valuation compare with the Healthcare sector?
| Metric | HLN | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 17.2 | 28.8 | 111 |
| Net margin | 14.55% | 4.31% | 164 |
| Return on equity | 9.89% | 5.47% | 185 |
| Dividend yield (payers) | 1.26% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
HLN price chart
Powered by TradingViewWhat does Haleon plc do?
Haleon Plc - ADR represents an American Depositary Receipt for Haleon Plc, a company known for its focus on consumer healthcare products. ADRs are traded on U.S. stock exchanges and allow American investors to invest in non-U.S. companies without dealing with foreign transactions. Haleon Plc specializes in providing health-related products across various categories, including oral health, pain relief, vitamins, minerals, and supplements, as well as digestive health and other wellness products. The company is a significant player in the global consumer healthcare market, serving regions worldwide. By offering solutions that cater directly to consumer health needs, Haleon's products find utilization in countless households, impacting consumer health and wellness sectors globally. As a spin-off from GlaxoSmithKline (GSK), Haleon continues its legacy of developing solutions aimed at improving everyday health, holding an important role within the healthcare industry due to its broad range of trusted brands and deep industry expertise.